Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. [electronic resource]
Producer: 20120820Description: 237-46 p. digitalISSN:- 1573-7217
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Hormonal -- adverse effects
- Biomarkers, Tumor -- metabolism
- Breast Neoplasms -- drug therapy
- Dose-Response Relationship, Drug
- Estradiol -- adverse effects
- Female
- Fulvestrant
- Humans
- Ki-67 Antigen -- metabolism
- Middle Aged
- Neoadjuvant Therapy
- Neoplasms, Hormone-Dependent -- drug therapy
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.